Quintrio
Home

Stock overview

Enlivex Ltd. Ordinary Shares

ENLV

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Last trade $1.15
Day change +$0.025 (+2.23%)
Day range $1.13 – $1.24
Volume 12,824
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.72M
Price / earnings
—
Price / book
0.05×
Price / sales
—
EV / sales
—
EV / EBITDA
0.41×

Profitability

Earnings per share
-$6.23
Return on assets
-23.66%
Return on equity
-26.9%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.72×
Quick ratio
8.72×
Cash ratio
1.3×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.03M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ENLV, quarterly periods
Line itemQ4 FY2020 Dec 31, 2020Q3 FY2020 Sep 30, 2020Q2 FY2020 Jun 30, 2020Q1 FY2020 Mar 31, 2020Q4 FY2019 Dec 31, 2019Q3 FY2019 Sep 30, 2019Q2 FY2019 Jun 30, 2019Q1 FY2019 Mar 31, 2019
Revenue————————
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit————————
Selling, general and administrative$1.55M$757K$873K$524K$1.09M$545K$601K$784K
Research and development$2.15M$1.2M$1.36M$1.37M$1.75M$1.58M$696K$1.58M
Total operating expenses$3.7M$1.96M$2.23M$1.9M$2.84M$2.12M$1.3M$2.36M
Operating income-$3.7M-$1.96M-$2.23M-$1.9M-$2.84M-$2.12M-$1.3M-$2.36M
Interest expense—-$223K-$897K-$2K—-$342K-$202K-$358K
Income before taxes-$5.86M-$2.13M-$3.04M-$794K-$2.87M-$2.39M-$1.46M-$2.67M
Income taxes————————
Net income-$5.86M-$2.13M-$3.04M-$794K-$2.87M-$2.39M-$1.46M-$2.67M
Net income attributable to common shareholders-$3.59M-$2.13M-$3.04M-$794K-$1.92M-$2.39M-$1.46M-$2.67M
EBITDA-$3.7M-$1.89M-$2.17M-$1.84M-$2.84M-$2.07M-$1.25M-$2.32M
Basic earnings per share-$103.20-$38.40-$55.20-$16.80-$74.40-$55.20-$33.60-$165.60
Diluted earnings per share-$103.20-$38.40-$55.20-$16.80-$74.40-$55.20-$33.60-$165.60

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch

RAIN, an Arbitrum-based prediction market protocol, announced $200 million in ecosystem commitments through a partnership with Enlivex and $100 million in liquidity expansion ($50M USDT, $50M RAIN). The protocol is preparing for Version 2 launch featuring permissionless market creation, AMMs, on-chain order books, and AI-assisted market resolution, with plans for major expansion around the FIFA World Cup.

GlobeNewswire Inc.

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 27, 20261-for-16reverse split
Jul 9, 20261-for-15reverse split
Mar 6, 20191-for-8reverse split
Sep 25, 20171-for-5reverse split